236 results on '"Moschini, Marco"'
Search Results
2. Long-term oncologic outcomes of robot-assisted radical cystectomy: update series from a high-volume robotic center beyond 10 years of follow-up
- Author
-
Bravi, Carlo A., Piazza, Pietro, Mazzone, Elio, Dell’Oglio, Paolo, Rosiello, Giuseppe, Martini, Alberto, Stabile, Armando, Moschini, Marco, Amato, Marco, Sarchi, Luca, Peraire, Maria, Farinha, Rui, Scarcella, Simone, Puliatti, Stefano, Knipper, Sophie, Berquin, Camille, Develtere, Dries, Sinatti, Celine, Van Puyvelde, Hannah, De Groote, Ruben, De Naeyer, Geert, D’Hondt, Frederiek, Schatteman, Peter, Briganti, Alberto, Montorsi, Francesco, and Mottrie, Alexandre
- Published
- 2023
- Full Text
- View/download PDF
3. Online Crowdfunding for Urologic Cancer Care
- Author
-
Rajwa, Pawel, Hopen, Philip, Wojnarowicz, Jakub, Kaletka, Julia, Paszkiewicz, Iga, Lach-Wojnarowicz, Olga, Mostafaei, Hadi, Krajewski, Wojciech, D’Andrea, David, Małkiewicz, Bartosz, Paradysz, Andrzej, Ploussard, Guillaume, Moschini, Marco, Breyer, Benjamin N, Pradere, Benjamin, Shariat, Shahrokh F, and Leapman, Michael S
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Urologic Diseases ,urology ,crowdfunding ,prostate cancer ,bladder cancer ,kidney cancer ,testicular cancer ,Oncology and carcinogenesis - Abstract
Background: we aimed to characterize the financial needs expressed through online crowdfunding for urologic cancers. Methods: the data used in this study came from the online crowdfunding platform GoFundMe.com. Using an automated software method, we extracted data for campaigns related to urologic cancers. Subsequently, four independent investigators reviewed all extracted data on prostate, bladder, kidney and testicular cancer. We analyzed campaigns’ basic characteristics, goals, fundraising, type of treatment and factors associated with successful campaigns. Results: in total, we identified 2126 individual campaigns, which were related to direct treatment costs (34%), living expenses (17%) or both (48%). Median fundraising amounts were greatest for testicular cancer. Campaigns for both complementary and alternative medicine (CAM) (median $11,000) or CAM alone (median $8527) achieved higher fundraising totals compared with those for conventional treatments alone (median $5362) (p < 0.01). The number of social media shares was independently associated with campaign success and highest quartile of fundraising. Conclusions: using an automated web-based approach, we identified and characterized online crowdfunding for urologic cancer care. These findings indicated a diverse range of patient needs related to urologic care and factors related to campaigns’ success.
- Published
- 2022
4. Background: State-of-the-Art and Ongoing Developments
- Author
-
Moschini, Marco, Marandino, Laura, Montorsi, Francesco, Necchi, Andrea, editor, and Spiess, Philippe E., editor
- Published
- 2022
- Full Text
- View/download PDF
5. Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomy
- Author
-
Arora, Amandeep, Zugail, Ahmed S., Pugliesi, Felipe, Cathelineau, Xavier, Macek, Petr, Barbé, Yann, Karnes, R. Jeffrey, Ahmed, Mohamed, Di Trapani, Ettore, Soria, Francesco, Alvarez-Maestro, Mario, Montorsi, Francesco, Briganti, Alberto, Necchi, Andrea, Pradere, Benjamin, D’Andrea, David, Krajewski, Wojciech, Roumiguié, Mathieu, Bajeot, Anne Sophie, Hurle, Rodolfo, Contieri, Roberto, Carando, Roberto, Teoh, Jeremy Yuen-Chun, Roupret, Morgan, Benamran, Daniel, Ploussard, Guillaume, Mir, M. Carmen, Sanchez-Salas, Rafael, and Moschini, Marco
- Published
- 2022
- Full Text
- View/download PDF
6. The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations
- Author
-
Del Giudice, Francesco, Flammia, Rocco Simone, Pecoraro, Martina, Moschini, Marco, D’Andrea, David, Messina, Emanuele, Pisciotti, Lucia Martina, De Berardinis, Ettore, Sciarra, Alessandro, and Panebianco, Valeria
- Published
- 2022
- Full Text
- View/download PDF
7. Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer
- Author
-
Afferi, Luca, Lonati, Chiara, Montorsi, Francesco, Briganti, Alberto, Necchi, Andrea, Mari, Andrea, Minervini, Andrea, Campi, Riccardo, di Trapani, Ettore, de Cobelli, Ottavio, Karnes, R. Jeffrey, Ahmed, Mohamed, Mir, M. Carmen, Algarra, Maria Asuncion, Rink, Michael, Zamboni, Stefania, Simeone, Claudio, Krajewski, Wojciech, Xylinas, Evanguelos, Soria, Francesco, Hendricksen, Kees, Einerhand, Sarah, Mattei, Agostino, Carando, Roberto, Roumiguié, Mathieu, Bajeot, Anne Sophie, Black, Peter C., Shariat, Shahrokh F., and Moschini, Marco
- Published
- 2022
- Full Text
- View/download PDF
8. Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer
- Author
-
Schuettfort, Victor M., Pradere, Benjamin, Trinh, Quoc-Dien, D’Andrea, David, Quhal, Fahad, Mostafaei, Hadi, Laukhtina, Ekaterina, Mori, Keiichiro, Sari Motlagh, Reza, Rink, Michael, Karakiewicz, Pierre I., Chlosta, Piotr, Yuen-Chun Teoh, Jeremy, Lotan, Yair, Scherr, Douglas, Abufaraj, Mohammad, Moschini, Marco, and Shariat, Shahrokh F.
- Published
- 2022
- Full Text
- View/download PDF
9. Radical Cystectomy
- Author
-
Ghodoussipour, Saum, Daneshmand, Siamak, Burkhard, Fiona C., Kiss, Bernhard, Thalmann, George N., Aldhaam, Naif A., Elsayed, Ahmed S., Hussein, Ahmed A., Guru, Khurshid A., Moschini, Marco, Saad, Mohamed, Cathelineau, Xavier, Sanchez-Salas, Rafael, Bansal, Utsav, Lerner, Seth P., Kamat, Ashish M., editor, and Black, Peter C., editor
- Published
- 2021
- Full Text
- View/download PDF
10. The optimal number of induction chemotherapy cycles in clinically lymph node‐positive bladder cancer.
- Author
-
von Deimling, Markus, Mertens, Laura S., Furrer, Marc, Li, Roger, Tendijck, Guus A.H., Taylor, Jacob, Crocetto, Felice, Maas, Moritz, Mari, Andrea, Pichler, Renate, Moschini, Marco, Tully, Karl H., D'Andrea, David, Laukhtina, Ekaterina, Del Giudice, Francesco, Marcq, Gautier, Velev, Maud, Gallioli, Andrea, Albisinni, Simone, and Mori, Keiichiro
- Subjects
INDUCTION chemotherapy ,BLADDER cancer ,LYMPHADENECTOMY ,LOGISTIC regression analysis ,SURVIVAL rate - Abstract
Objective: To investigate the optimal number of induction chemotherapy cycles needed to achieve a pathological response in patients with clinically lymph node‐positive (cN+) bladder cancer (BCa) who received three or four cycles of induction chemotherapy followed by consolidative radical cystectomy (RC) with pelvic lymph node dissection. Patients and Methods: We included 388 patients who received three or four cycles of cisplatin/gemcitabine or (dose‐dense) methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), followed by consolidative RC for cTanyN1–3M0 BCa. We compared pathological complete (pCR = ypT0N0) and objective response (pOR = yp ≤T1N0) between treatment groups. Predictors of pCR and/or pOR were assessed using uni‐ and multivariable logistic regression analysis. The secondary endpoints were overall (OS) and cancer‐specific survival (CSS). We evaluated the association between the number of induction chemotherapy cycles administered and survival outcomes on multivariable Cox regression. Results: Overall, 101 and 287 patients received three or four cycles of induction chemotherapy, respectively. Of these, 72 (19%) and 128 (33%) achieved pCR and pOR response, respectively. The pCR (20%, 18%) and pOR (40%, 31%) rates did not differ significantly between patients receiving three or four cycles (P > 0.05). The number of cycles was not associated with pCR or pOR on multivariable logistic regression analyses. The 2‐year OS estimates were 63% (95% confidence interval [CI] 0.53–0.74) and 63% (95% CI 0.58–0.7) for patients receiving three or four cycles, respectively. Receiving three vs four cycles was not associated with OS and CSS on uni‐ or multivariable Cox regression analyses. Conclusion: Pathological response and survival outcomes did not differ between administering three or four induction chemotherapy cycles in patients with cN+ BCa. A fewer cycles (minimum three) may be oncologically sufficient in patients with cN+ BCa, while decreasing the wait for definitive local therapy in those patients who end up without a response to chemotherapy. This warrants further validation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Perioperative Outcomes and Trends in Transurethral Resection of Bladder Tumors with Photodynamic Diagnosis: Results from the GeRmAn Nationwide Inpatient Data Study.
- Author
-
Pyrgidis, Nikolaos, Moschini, Marco, Tzelves, Lazaros, Somani, Bhaskar K., Juliebø-Jones, Patrick, Del Giudice, Francesco, Mertens, Laura S., Pichler, Renate, Volz, Yannic, Ebner, Benedikt, Eismann, Lennert, Semmler, Marie, Pradere, Benjamin, Soria, Francesco, Stief, Christian G., and Schulz, Gerald B.
- Subjects
- *
TRANSURETHRAL resection of bladder , *BLADDER cancer , *TUMOR diagnosis , *HOSPITAL admission & discharge , *LOGISTIC regression analysis , *INTENSIVE care units - Abstract
Background: Photodynamic diagnosis (PDD) during transurethral resection of bladder tumor (TURBT) is guideline recommended, as it improves bladder cancer detection rates. However, the extent to which PDD is implemented in everyday clinical practice has not been thoroughly assessed. We aimed to evaluate the current trends and major perioperative outcomes of TURBT with PDD. Methods: The present study evaluated the GeRmAn Nationwide inpatient Data (GRAND) from 2010 (the year when PDD started to be coded separately in Germany) to 2021, which were made available from the Research Data Center of the German Bureau of Statistics. We undertook numerous patient-level and multivariable logistic regression analyses. Results: Overall, 972,208 TURBTs [228,207 (23%) with PDD and 744,001 (77%) with white light] were performed. Patients offered PDD during TURBT were younger (p < 0.001), presented fewer comorbidities (p < 0.001) and were discharged earlier from hospital (p < 0.001). PDD was associated with additional costs of about EUR 500 compared to white-light TURBT (p < 0.001). The yearly TURBT cases remained relatively stable from 2010 to 2021, whereas utilization of PDD underwent a 2-fold increase. After adjusting for major risk factors in the multivariate regression analysis, PDD was related to lower rates of transfusion (1.4% vs. 5.6%, OR: 0.29, 95% CI: 0.28 to 0.31, p < 0.001), intensive care unit admission (0.7% vs. 1.4%, OR: 0.56, 95% CI: 0.53 to 0.59, p < 0.001) and 30-day in-hospital mortality (0.1% vs. 0.7%, OR: 0.24, 95% CI: 0.22 to 0.27, p < 0.001) compared to white-light TURBT. On the contrary, PDD was related to clinically insignificant higher rates of bladder perforation (0.6% versus 0.5%, OR: 1.3, 95% CI: 1.2 to 1.4, p < 0.001), and reoperation (2.6% versus 2.3%, OR: 1.2, 95% CI: 1.1 to 1.2, p < 0.001). Conclusions: The utilization of PDD with TURBT is steadily increasing. Nevertheless, the road toward the establishment of PDD as the standard of care for TURBT is still long, despite of the advantages of PDD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Variation in Follow-Up after Radical Cystectomy for Bladder Cancer—An Inventory Roundtable and Literature Review.
- Author
-
Contieri, Roberto, Pichler, Renate, del Giudice, Francesco, Marcq, Gautier, Gallioli, Andrea, Albisinni, Simone, Soria, Francesco, d'Andrea, David, Krajewski, Wojciech, Carrion, Diego M., Mari, Andrea, van Rhijn, Bas W. G., Moschini, Marco, Pradere, Benjamin, and Mertens, Laura S.
- Subjects
LITERATURE reviews ,BLADDER cancer ,CYSTECTOMY ,TRANSITIONAL cell carcinoma ,INVENTORIES ,COMPUTED tomography - Abstract
Background: Follow-up after radical cystectomy (RC) for bladder cancer can be divided into oncological and functional surveillance. It remains unclear how follow-up after RC should ideally be scheduled. The aim of this report was to gain insight into the organization of follow-up after RC in Europe, for which we conducted a roundtable inventory within the EAU Young Academic Urologists Urothelial Cancer working group. Methods: An inventory semi-structured survey was performed among urologists of the EAU Young Academic Urologists Urothelial Cancer working group to describe the organization of follow-up. The surveys were analyzed using a deductive approach. Similarities and differences in follow-up after RC for bladder cancer were described. Results: The survey included 11 urologists from six different European countries. An institutional follow-up scheme was used by six (55%); three (27%) used a national or international guideline, and two (18%) indicated that there was no defined follow-up scheme. Major divergent aspects included the time points of follow-up, the frequency, and the end of follow-up. Six centers (55%) adopted a risk-adapted follow-up approach tailored to (varying) patient and tumor characteristics. Laboratory tests and CT scans were used in all cases; however, the intensity and frequency varied. Functional follow-up overlapped with oncological follow-up in terms of frequency and duration. Patient-reported outcome measures were only used by two (18%) urologists. Conclusions: Substantial variability exists across European centers regarding the follow-up after RC for bladder cancer. This highlights the need for an international analysis focusing on its organization and content as well as on opportunities to improve patients' needs during follow-up after RC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent
- Author
-
Zamboni, Stefania, Afferi, Luca, Soria, Francesco, Aziz, Atiqullah, Abufaraj, Mohammad, Poyet, Cedric, Necchi, Andrea, D’Andrea, David, Simone, Giuseppe, Ferriero, Mariaconsiglia, Di Trapani, Ettore, Simeone, Claudio, Antonelli, Alessandro, Gallina, Andrea, Montorsi, Francesco, Briganti, Alberto, Colombo, Renzo, Gandaglia, Giorgio, Mattei, Agostino, Baumeister, Philipp, Mordasini, Livio, Hendricksen, Kees, Voskuilen, Charlotte S., Rink, Michael, Shariat, Shahrokh F., Xylinas, Evanguelous, and Moschini, Marco
- Published
- 2021
- Full Text
- View/download PDF
14. The impact of preoperative nutritional status on post-surgical complication and mortality rates in patients undergoing radical cystectomy for bladder cancer: a systematic review of the literature
- Author
-
Ornaghi, Paola Irene, Afferi, Luca, Antonelli, Alessandro, Cerruto, Maria Angela, Odorizzi, Katia, Gozzo, Alessandra, Mordasini, Livio, Mattei, Agostino, Baumeister, Philipp, Cornelius, Julian, Tafuri, Alessandro, and Moschini, Marco
- Published
- 2021
- Full Text
- View/download PDF
15. Treating BCG-Induced Cystitis with Combined Chondroitin and Hyaluronic Acid Instillations in Bladder Cancer.
- Author
-
Pichler, Renate, Stäblein, Johannes, Mari, Andrea, Afferi, Luca, D'Andrea, David, Marcq, Gautier, del Giudice, Francesco, Soria, Francesco, Caño-Velasco, Jorge, Subiela, José Daniel, Gallioli, Andrea, Tully, Karl H., Mori, Keiichiro, Herms, Achim, Pradere, Benjamin, Moschini, Marco, Mertens, Laura S., and Thurnher, Martin
- Subjects
BLADDER cancer ,NON-muscle invasive bladder cancer ,HYALURONIC acid ,CHONDROITIN ,CYSTITIS ,BCG immunotherapy - Abstract
In non-muscle invasive bladder cancer, Bacillus Calmette–Guérin (BCG) responders benefit from strong Th1-type inflammatory and T cell responses mediating tumor rejection. However, the corresponding lack of anti-inflammatory Th2-type immunity impairs tissue repair in the bladder wall and facilitates the development of cystitis, causing urinary pain, urgency, incontinence, and frequency. Mechanistically, the leakage of the glycosaminoglycan (GAG) layer enables an influx of potassium ions, bacteria, and urine solutes towards the underlying bladder tissue, promoting chronic inflammation. Treatments directed towards re-establishing this mucopolysaccharide-based protective barrier are urgently needed. We discuss the pathomechanisms, as well as the therapeutic rationale of how chondroitin and hyaluronic acid instillations can reduce or prevent BCG-induced irritative bladder symptoms. Moreover, we present a case series of five patients with refractory BCG-induced cystitis successfully treated with combined chondroitin and hyaluronic acid instillations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Non-Surgical Bladder-Sparing Multimodal Management in Organ-Confined Urothelial Carcinoma of the Urinary Bladder: A Population-Based Analysis.
- Author
-
de Angelis, Mario, Baudo, Andrea, Siech, Carolin, Jannello, Letizia Maria Ippolita, Di Bello, Francesco, Goyal, Jordan A., Tian, Zhe, Longo, Nicola, de Cobelli, Ottavio, Chun, Felix K. H., Saad, Fred, Shariat, Shahrokh F., Carmignani, Luca, Gandaglia, Giorgio, Moschini, Marco, Montorsi, Francesco, Briganti, Alberto, and Karakiewicz, Pierre I.
- Subjects
BLADDER tumors ,MULTIVARIATE analysis ,DESCRIPTIVE statistics ,TRANSITIONAL cell carcinoma ,KAPLAN-Meier estimator ,COMBINED modality therapy - Abstract
Simple Summary: Radical cystectomy represents the gold-standard treatment for organ-confined urothelial carcinoma of the urinary bladder. However, it does not represent a treatment option for some patients unfit for major surgery or wanting to preserve their bladder. In consequence, non-surgical bladder-sparing multimodal strategies are gaining popularity. Among these, the combination of transurethral resection, chemotherapy, and radiotherapy (namely trimodal therapy) represents the most recognized and validated treatment option. However, some patients may only be eligible for either chemotherapy or radiotherapy but not both. The aim of this study was to evaluate cancer-specific mortality differences among these treatments. We ascertained that when radical cystectomy is not an option, strict trimodal therapy that includes both chemotherapy and radiotherapy after transurethral resection offers the best cancer control. Additionally, when strict trimodal therapy cannot be delivered, chemotherapy represents the second-best option. Finally, radiotherapy without chemotherapy offers the worst cancer control. Background: Trimodal therapy is considered the most validated bladder-sparing treatment in patients with organ-confined urothelial carcinoma of the urinary bladder (T2N0M0). However, scarce evidence exists regarding cancer-specific mortality (CSM) differences between trimodal therapy and other non-extirpative multimodal treatment options such as radiotherapy alone after transurethral resection (TURBT + RT) or chemotherapy alone after transurethral resection (TURBT + CT). Methods: Within the Surveillance, Epidemiology, and End Results database (2004–2020), we identified T2N0M0 patients treated with either trimodal therapy, TURBT + CT, or TURBT + RT. Temporal trends described trimodal therapy vs. TUBRT + CT vs. TURBT + RT use over time. Survival analyses consisting of Kaplan–Meier plots and multivariable Cox regression (MCR) models addressed CSM according to each treatment modality. Results: 3729 (40%) patients underwent TMT vs. 4030 (43%) TURBT + CT vs. 1599 (17%) TURBT + RT. Over time, trimodal therapy use (Estimating annual percent change, EAPC: +1.2%, p = 0.01) and TURBT + CT use increased (EAPC: +1.5%, p = 0.01). In MCR models, relative to trimodal therapy, TURBT + CT exhibited 1-14-fold higher CSM and TURBT + RT 1.68-fold higher CSM. In a subgroup analysis, TURBT + RT was associated with 1.42-fold higher CSM than TURBT + CT (p < 0.001). Conclusions: Strict trimodal therapy that includes both CT and RT after TURBT offers the best cancer control. When strict trimodal therapy cannot be delivered, cancer-specific survival outcomes appear to be superior with TURBT + chemotherapy compared to TURBT + RT. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Effectiveness of Preoperative Immunonutrition in Improving Surgical Outcomes after Radical Cystectomy for Bladder Cancer: Study Protocol for a Multicentre, Open-Label, Randomised Trial (INu-RC).
- Author
-
Da Prat, Valentina, Aretano, Lucia, Moschini, Marco, Bettiga, Arianna, Crotti, Silvia, De Simeis, Francesca, Cereda, Emanuele, Casirati, Amanda, Pontara, Andrea, Invernizzi, Federica, Klersy, Catherine, Gambini, Giulia, Musella, Valeria, Marchetti, Carlo, Briganti, Alberto, Cotogni, Paolo, Naspro, Richard, Montorsi, Francesco, and Caccialanza, Riccardo
- Subjects
CYSTECTOMY ,BLADDER tumors ,PREOPERATIVE care ,RANDOMIZED controlled trials ,ENTERAL feeding ,OPERATIVE surgery ,QUALITY assurance ,DIETARY supplements - Abstract
Radical cystectomy (RC) with pelvic lymph node dissection is the standard treatment for patients with limited-stage muscle-invasive bladder cancer. RC is associated with a complication rate of approximately 50–88%. Immunonutrition (IMN) refers to the administration of substrates, such as omega-3 fatty acids, arginine, glutamine, and nucleotides, that modulate the immune response. IMN has been associated with improved outcomes following surgery for esophagogastric, colorectal and pancreatic cancer. In this paper, we describe a study protocol for a multicentre, randomised, open-label clinical trial to evaluate the effect of IMN in patients undergoing RC for bladder cancer. A 7-day preoperative course of IMN is compared with a standard high-calorie high-protein oral nutritional supplement. The primary outcome of this study is the rate of complications (infectious, wound-related, gastrointestinal, and urinary complications) in the first 30 days after RC. Secondary outcomes include time to recovery of bowel function and postoperative mobilisation, changes in muscle strength and body weight, biochemical modifications, need for blood transfusion, length of stay, readmission rate, and mortality. The results of this study may provide new insights into the impact of IMN on postoperative outcomes after RC and may help improve IMN prescribing based on patient nutritional status parameters. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node‐positive bladder cancer.
- Author
-
von Deimling, Markus, Furrer, Marc, Mertens, Laura S., Mari, Andrea, van Ginkel, Noor, Bacchiani, Mara, Maas, Moritz, Pichler, Renate, Li, Roger, Moschini, Marco, Bianchi, Alberto, Vetterlein, Malte W., Lonati, Chiara, Crocetto, Felice, Taylor, Jacob, Tully, Karl H., Afferi, Luca, Soria, Francesco, del Giudice, Francesco, and Longoni, Mattia
- Subjects
LYMPHADENECTOMY ,SURVIVAL rate ,BLADDER cancer ,INDUCTION chemotherapy ,LOGISTIC regression analysis - Abstract
Objective: To determine the oncological impact of extended pelvic lymph node dissection (ePLND) vs standard PLND (sPLND) during radical cystectomy (RC) in clinically lymph node‐positive (cN+) bladder cancer (BCa). Patients and Methods: In this retrospective, multicentre study we included 969 patients who underwent RC with sPLND (internal/external iliac and obturator lymph nodes) or ePLND (sPLND plus common iliac and presacral nodes) with or without platin‐based peri‐operative chemotherapy for cTany N1‐3 M0 BCa between 1991 and 2022. We assessed the impact of ePLND on recurrence‐free survival (RFS) and the distribution of recurrences (locoregional and distant recurrences). The secondary endpoint was overall survival (OS). We performed propensity‐score matching using covariates associated with the extent of PLND in univariable logistic regression analysis. The association of the extent of PLND with RFS and OS was investigated using Cox regression models. Results: Of 969 cN+ patients, 510 were 1:1 matched on propensity scores. The median (interquartile range [IQR]) time to recurrence was 8 (4–16) months, and median (IQR) follow‐up of alive patients was 30 (13–51) months. Disease recurrence was observed in 104 patients in the ePLND and 107 in the sPLND group. Of these, 136 (27%), 47 (9.2%) and 19 patients (3.7%) experienced distant, locoregional, or both distant and locoregional disease recurrence, respectively. When stratified by the extent of PLND, we did not find a difference in recurrence patterns (P > 0.05). ePLND improved neither RFS (hazard ratio [HR] 0.91, 95% confidence interval [CI] 0.70–1.19; P = 0.5) nor OS (HR 0.78, 95% CI 0.60–1.01; P = 0.06) compared to sPLND. Stratification by induction chemotherapy did not change outcomes. Conclusion: Performing an ePLND at the time of RC in cN+ patients improved neither RFS nor OS compared to sPLND, regardless of induction chemotherapy status. Pretreatment risk stratification is paramount to identify ideal candidates for RC with ePLND as part of a multimodal treatment approach. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Urinary function in female patients after traditional, organ‐sparing and nerve‐sparing radical cystectomy for bladder cancer: a systematic review and pooled analysis.
- Author
-
Laukhtina, Ekaterina, von Deimling, Markus, Pradere, Benjamin, Yanagisawa, Takafumi, Rajwa, Pawel, Kawada, Tatsushi, Quhal, Fahad, Pallauf, Maximilian, Bianchi, Alberto, Majdoub, Muhammad, Mostafaei, Hadi, Sari Motlagh, Reza, Mori, Keiichiro, Enikeev, Dmitry, Fisch, Margit, Moschini, Marco, D'Andrea, David, Soria, Francesco, Albisinni, Simone, and Fajkovic, Harun
- Subjects
URINARY diversion ,WOMEN patients ,BLADDER cancer ,CYSTECTOMY ,SCIENCE databases ,WEB databases - Abstract
Objectives: To determine and summarize the available data on urinary, sexual, and health‐related quality‐of‐life (HRQOL) outcomes after traditional radical cystectomy (RC), reproductive organ‐preserving RC (ROPRC) and nerve‐sparing RC (NSRC) for bladder cancer (BCa) in female patients. Methods: The PubMed, SCOPUS and Web of Science databases were searched to identify studies reporting functional outcomes in female patients undergoing RC and urinary diversion for the treatment of BCa. The outcomes of interest were voiding function (for orthotopic neobladder [ONB]), sexual function and HRQOL. The following independent variables were derived and included in the meta‐analysis: pooled rate of daytime and nighttime continence/incontinence, and intermittent self‐catheterization (ISC) rates. Analyses were performed separately for traditional, organ‐ and/or nerve‐sparing surgical approaches. Results: Fifty‐three studies comprising 2740 female patients (1201 traditional RC and 1539 organ‐/nerve‐sparing RC, and 264 nerve‐sparing‐alone RC) were eligible for qualitative synthesis; 44 studies comprising 2418 female patients were included in the quantitative synthesis. In women with ONB diversion, the pooled rates of daytime continence after traditional RC, ROPRC and NSRC were 75.2%, 79.3% and 71.2%, respectively. The pooled rate of nighttime continence after traditional RC was 59.5%; this rate increased to 70.7% and 71.7% in women who underwent ROPRC and NSRC, respectively. The pooled rate of ISC after traditional RC with ONB diversion in female patients was 27.6% and decreased to 20.6% and 16.8% in patients undergoing ROPRC and NSRC, respectively. The use of different definitions and questionnaires in the assessment of postoperative sexual and HRQOL outcomes did not allow a systematic comparison. Conclusions: Female organ‐ and nerve‐sparing surgical approaches during RC seem to result in improved voiding function. There is a significant need for well‐designed studies exploring sexual and HRQOL outcomes to establish evidence‐based management strategies to support a shared decision‐making process tailored towards patient expectations and satisfaction. Understanding expected functional, sexual and quality‐of‐life outcomes is necessary to allow individualized pre‐ and postoperative counselling and care delivery in female patients planned to undergo RC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Vesical Imaging‐Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle‐invasive bladder cancer.
- Author
-
Necchi, Andrea, Basile, Giuseppe, Gibb, Ewan A., Raggi, Daniele, Calareso, Giuseppina, de Padua, Tiago Costa, Patanè, Damiano, Crupi, Emanuele, Mercinelli, Chiara, Cigliola, Antonio, Tateo, Valentina, Giannatempo, Patrizia, Moschini, Marco, Briganti, Alberto, Montorsi, Francesco, Messina, Antonella, Ross, Jeffrey S., Pavlick, Dean, De Cobelli, Francesco, and Brembilla, Giorgio
- Subjects
CANCER invasiveness ,BLADDER cancer ,PEMBROLIZUMAB ,MAGNETIC resonance imaging ,REGRESSION analysis - Abstract
Objective: To evaluate the predictive capability of the pre‐ and post‐pembrolizumab Vesical Imaging–Reporting and Data System (VI‐RADS) to identify ypT0N0 or ypT≤1N0 response in muscle‐invasive bladder cancer (MIBC) within the PURE‐01 trial (ClinicalTrials.gov identifier: NCT02736266). Patients and Methods: Patients were staged with bladder multiparametric magnetic resonance imaging (mpMRI) before and after treatment (three cycles of pembrolizumab) prior to radical cystectomy (RC). Logistic regression models were used to analyse the pre‐ and post‐ pembrolizumab VI‐RADS against ypT≤1N0 and ypT0N0 response. The VI‐RADS scores were dichotomised between 0 and 3 (0 = no evidence of disease) and 4–5. Event‐free survival (EFS) and overall survival (OS) analyses were performed. Comprehensive genomic profiling and transcriptome‐wide expression profiling data were matched with the VI‐RADS scores. Results: In total, 110 patients underwent centrally reviewed scans (N = 220 mpMRI), treated between February 2017 and July 2020. Both pre‐ and post‐pembrolizumab VI‐RADS 0–3 scores were the only significant covariates that predicted the ypT≤1N0 endpoint in multivariable analyses, and the strongest effect was seen with post‐pembrolizumab VI‐RADS 0–3 predicting the ypT≤1N0 response (P < 0.001). The area under the curve for this model was 0.90. Post‐pembrolizumab VI‐RADS 0–3 also predicted a longer EFS (P < 0.001) and OS (P = 0.044). The scores of several gene signatures from baseline tumours differed between the pre‐pembrolizumab VI‐RADS 0–3 and 4–5 categories. Conclusion: Post‐pembrolizumab VI‐RADS scores are strongly associated with pathological downstaging and survival. VI‐RADS scores were also characterised by distinct biomarker features. These results indicate that the VI‐RADS is emerging as an important tool for designing next‐generation trials for MIBC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Long‐term functional outcomes after robot‐assisted radical cystectomy with intracorporeal ileal orthotopic neobladder.
- Author
-
Pellegrino, Francesco, Scilipoti, Pietro, Rosiello, Giuseppe, Longoni, Mattia, Leni, Riccardo, Basile, Giuseppe, Quarta, Leonardo, Zaurito, Paolo, Re, Chiara, de Angelis, Mario, Cattafi, Francesco, Burgio, Giusy, Gandaglia, Giorgio, Montorsi, Francesco, Briganti, Alberto, and Moschini, Marco
- Subjects
ILEAL conduit surgery ,URINARY diversion ,FUNCTIONAL status ,SURGICAL robots ,CYSTECTOMY ,KEGEL exercises ,PHYSICIANS - Abstract
This article discusses the long-term functional outcomes of robot-assisted radical cystectomy (RARC) with intracorporeal ileal orthotopic neobladder (iNeoB) for the treatment of bladder cancer. The study included 81 men who underwent RARC with iNeoB and were followed up for a median of 41 months. The results showed that 78% of patients regained urinary continence (UC) and 47% regained erectile function (EF) at 2 years of follow-up. The study also evaluated the use of clean intermittent catheterization (CIC) and bowel function (BF) recovery, finding that the 2-year rate of CIC was 13% and 87% of patients reached regular BF after 2 years. The authors suggest that these findings can be used to provide realistic expectations to patients undergoing RARC with iNeoB and emphasize the importance of long-term follow-up for assessing EF recovery. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
22. How to improve patient selection for neoadjuvant chemotherapy in bladder cancer patients candidate for radical cystectomy and pelvic lymph node dissection
- Author
-
Zamboni, Stefania, Moschini, Marco, Antonelli, Alessandro, Simeone, Claudio, Belotti, Sandra, Cristinelli, Luca, Montorsi, Francesco, Briganti, Alberto, Gallina, Andrea, Salonia, Andrea, Colombo, Renzo, Mordasini, Livio, Mattei, Agostino, and Baumeister, Philipp
- Published
- 2020
- Full Text
- View/download PDF
23. The impact of completeness of last transurethral resection of bladder tumors on the outcomes of radical cystectomy
- Author
-
Zamboni, Stefania, Moschini, Marco, Gallina, Andrea, Colombo, Renzo, Montorsi, Francesco, Briganti, Alberto, Salonia, Andrea, Antonelli, Alessandro, Simeone, Claudio, Belotti, Sandra, Cristinelli, Luca, Mattei, Agostino, and Baumeister, Philipp
- Published
- 2019
- Full Text
- View/download PDF
24. The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer
- Author
-
Moschini, Marco, Zaffuto, Emanuele, Karakiewicz, Pierre, Mattei, Agostino, Gandaglia, Giorgio, Fossati, Nicola, Montorsi, Francesco, Briganti, Alberto, and Shariat, Shahrokh F.
- Published
- 2019
- Full Text
- View/download PDF
25. Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study
- Author
-
Zattoni, Fabio, Incerti, Elena, Colicchia, Michele, Castellucci, Paolo, Panareo, Stefano, Picchio, Maria, Fallanca, Federico, Briganti, Alberto, Moschini, Marco, Gallina, Andrea, Karnes, Jeffrey R., Lowe, Val, Fanti, Stefano, Schiavina, Riccardo, Rambaldi, Ilaria, Ficarra, Vincenzo, and Evangelista, Laura
- Published
- 2018
- Full Text
- View/download PDF
26. Contemporary rates of adherence to international guidelines for pelvic lymph node dissection in radical cystectomy: a population-based study
- Author
-
Zaffuto, Emanuele, Bandini, Marco, Gazdovich, Stéphanie, Valiquette, Anne-Sophie, Leyh-Bannurah, Sami-Ramzi, Tian, Zhe, Dell’Oglio, Paolo, Graefen, Markus, Moschini, Marco, Necchi, Andrea, Shariat, Shahrokh F., Briganti, Alberto, Montorsi, Francesco, and Karakiewicz, Pierre I.
- Published
- 2018
- Full Text
- View/download PDF
27. Oncological and safety profiles in patients undergoing simultaneous <scp>transurethral resection (TUR) of bladder tumour</scp> and <scp>TUR of the prostate</scp>
- Author
-
Laukhtina, Ekaterina, Moschini, Marco, Krajewski, Wojciech, Teoh, Jeremy Yuen-Chun, Ploussard, Guillaume, Soria, Francesco, Roghmann, Florian, Muenker, Mara Anna, Roumiguie, Mathieu, Alvarez-Maestro, Mario, Misrai, Vincent, Antonelli, Alessandro, Tafuri, Alessandro, Simone, Giuseppe, Mastroianni, Riccardo, Zhao, Hongda, Rahota, Razvan-George, D'Andrea, David, Mori, Keiichiro, Albisinni, Simone, Karakiewicz, Pierre I, Fajkovic, Harun, Enikeev, Dmitry, Montorsi, Francesco, Shariat, Shahrokh F, and Pradere, Benjamin
- Subjects
#UroBPH ,#blcsm ,#uroonc ,TURP ,Settore MED/24 ,TURB ,BPH ,Urology ,#BladderCancer ,bladder cancer ,simultaneous - Abstract
To determine the oncological impact and adverse events of performing simultaneous transurethral resection of bladder tumour (TURB) and transurethral resection of the prostate (TURP), as evidence on the outcomes of simultaneous TURB for bladder cancer and TURP for obstructive benign prostatic hyperplasia is limited and contradictory.Patients from 12 European hospitals treated with either TURB alone or simultaneous TURB and TURP (TURB+TURP) were retrospectively analysed. A propensity score matching (PSM) 1:1 was performed with patients from the TURB+TURP group matched to TURB-alone patients. Associations between surgery approach with recurrence-free (RFS) and progression-free (PFS) survivals were assessed in Cox regression models before and after PSM. We performed a subgroup analysis in patients with risk factors for recurrence (multifocality and/or tumour size3 cm).A total of 762 men were included, among whom, 76% (581) underwent a TURB alone and 24% (181) a TURB+TURP. There was no difference in terms of tumour characteristics between the groups. We observed comparable length of stay as well as complication rates including major complications (Clavien-Dindo Grade ≥III) for the TURB-alone vs TURB+TURP groups, while the latest led to longer operative time (P 0.001). During a median follow-up of 44 months, there were more recurrences in the TURB-alone (47%) compared to the TURB+TURP group (28%; P 0.001). Interestingly, there were more recurrences at the bladder neck/prostatic fossa in the TURB-alone group (55% vs 3%, P 0.001). TURB+TURP procedures were associated with improved RFS (hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.29-0.53; P 0.001), but not PFS (HR 1.63, 95% CI 0.90-2.98; P = 0.11). Within the PSM cohort of 254 patients, the simultaneous TURB+TURP was still associated with improved RFS (HR 0.33, 95% CI 0.22-0.49; P 0.001). This was also true in the subgroup of 380 patients with recurrence risk factors (HR 0.41, 95% CI 0.28-0.62; P 0.001).In our contemporary cohort, simultaneous TURB and TURP seems to be an oncologically safe option that may, even, improve RFS by potentially preventing disease recurrence at the bladder neck and in the prostatic fossa.
- Published
- 2022
28. Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy
- Author
-
Moschini, Marco, Mattei, Agostino, Cornelius, Julian, Shariat, Shahrokh F., Dell’Oglio, Paolo, Zaffuto, Emanuele, Salonia, Andrea, Montorsi, Francesco, Briganti, Alberto, Colombo, Renzo, and Gallina, Andrea
- Published
- 2018
- Full Text
- View/download PDF
29. Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder
- Author
-
Abufaraj, Mohammad, Shariat, Shahrokh F., Foerster, Beat, Pozo, Carmen, Moschini, Marco, D’Andrea, David, Mathieu, Romain, Susani, Martin, Czech, Anna K., Karakiewicz, Pierre I., and Seebacher, Veronika
- Published
- 2017
- Full Text
- View/download PDF
30. Intravesical BCG in bladder cancer induces innate immune responses against SARS-CoV-2.
- Author
-
Pichler, Renate, Diem, Gabriel, Hackl, Hubert, Koutník, Jiří, Mertens, Laura S., D'Andrea, David, Pradere, Benjamin, Soria, Francesco, Mari, Andrea, Laukhtina, Ekaterina, Krajewski, Wojciech, Jeremy Yuen-Chun Teoh, Del Guidice, Francesco, Moschini, Marco, Thurnher, Martin, and Posch, Wilfried
- Subjects
BCG vaccines ,BCG immunotherapy ,IMMUNE response ,MONONUCLEAR leukocytes ,BLADDER cancer ,SARS-CoV-2 - Abstract
BCG is the most efficient adjuvant therapy for high-risk, non-muscle-invasive bladder cancer (NMIBC). Both innate and adaptive immune responses have been implicated in BCG-mediated effects. BCG vaccination can boost innate immune responses via trained immunity (TI), resulting in an increased resistance to respiratory viral infections. Here we evaluated for the first time whether intravesical application of BCG triggers increased immunity against SARS-CoV-2 in patients with high-risk NMIBC. Serum and peripheral blood mononuclear cells (PBMCs) from heparinized whole blood samples of 11 unvaccinated SARSCoV-2-naïve high-risk NMIBC patients were collected at baseline and during BCG treatment in a pre-COVID-19 era. To examine B-cell or T cell-dependent adaptive immunity against SARS-CoV-2, sera were tested for the presence of SARS-CoV-2 neutralizing antibodies. Using a SARS-CoV-2 peptide pool, virusspecific T cells were quantified via IFNg ELISpot assays. To analyze innate immune responses, mRNA and protein expression levels of pro- and anti-inflammatory cytokines were measured after a 24-hour stimulation of PBMCs with either BCG or SARS-CoV-2 wildtype. ATAC-sequencing was performed to identify a potential epigenetic reprogramming in immune cells. We neither identified SARS-CoV-2 neutralizing antibodies nor SARS-CoV-2-reactive T cells, indicating that intravesical BCG did not induce adaptive immunity against SARS-CoV-2. However, a significant increase in mRNA as well as protein expression of IL-1β, IL-6 and TNFa, which are key cytokines of trained immunity, could be observed after at least four intravesical BCG instillations. Genomic regions in the proximity of TI genes (TLR2, IGF1R, AKT1, MTOR, MAPK14, HSP90AA1) were more accessible during BCG compared to baseline. Although intravesical BCG did not induce adaptive immune responses, repetitive intravesical instillations of BCG induced circulating innate immune cells that produce TI cytokines also in response to SARS-CoV-2. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Assessing the Performance of 18F-FDG PET/CT in Bladder Cancer: A Narrative Review of Current Evidence.
- Author
-
Bacchiani, Mara, Salamone, Vincenzo, Massaro, Eleana, Sandulli, Alessandro, Mariottini, Riccardo, Cadenar, Anna, Di Maida, Fabrizio, Pradere, Benjamin, Mertens, Laura S., Longoni, Mattia, Krajewski, Wojciech, Del Giudice, Francesco, D'Andrea, David, Laukhtina, Ekaterina, Shariat, Shahrokh F., Minervini, Andrea, Moschini, Marco, and Mari, Andrea
- Subjects
BLADDER tumors ,ONLINE information services ,MEDICAL information storage & retrieval systems ,SYSTEMATIC reviews ,METASTASIS ,LYMPH nodes ,TUMOR classification ,RADIOPHARMACEUTICALS ,POSITRON emission tomography ,DEOXY sugars ,COMPUTED tomography ,PHYSICIANS ,MEDLINE ,SENSITIVITY & specificity (Statistics) ,COMBINED modality therapy - Abstract
Simple Summary: Lymph node involvement is a prognostic determinant in the diagnostic work-up and management of muscle-invasive bladder cancer. Thus, it is crucial to provide an accurate staging of the bladder tumor to better identify the best therapeutic strategies to improve the chances of survival and the quality of life of patients affected by bladder cancer. Positron Emission Tomography/Computed Tomography (PET/CT) has been increasingly used in bladder cancer staging to improve the accuracy of lymph node detection and to overcome the lack of sensitivity and the understaging showed by conventional imaging. The aim of this narrative literature review is to provide an overview of the current evidence on the use of 18F-FDG PET/CT in the diagnosis, staging, and restaging of bladder cancer, with a particular focus on its sensitivity and specificity for the detection of LN metastasis. We aim to provide clinicians with a better understanding of 18F-FDG PET/CT's potential benefits and limitations in clinical practice. Despite the heterogeneity of the studies in the literature and the lack of a consensus, 18F-FDG PET/CT provides important incremental staging and restaging information that can potentially influence the clinical management of patients affected by muscle-invasive bladder cancer. Introduction: Lymph node (LN) involvement is a crucial determinant of prognosis for patients with bladder cancer, and an accurate staging is of utmost importance to better identify timely and appropriate therapeutic strategies. To improve the accuracy of LN detection, as an alternative to traditional methods such as CT or MRI, 18F-FDG PET/CT has been increasingly used. 18F-FDG PET/CT is also used in post-treatment restaging after neoadjuvant chemotherapy. The aim of this narrative literature review is to provide an overview of the current evidence on the use of 18F-FDG PET/CT in the diagnosis, staging, and restaging of bladder cancer, with a particular focus on its sensitivity and specificity for the detection of LN metastasis. We aim to provide clinicians with a better understanding of 18F-FDG PET/CT's potential benefits and limitations in clinical practice. Materials and Methods: We designed a narrative review starting from a wide search in the PubMed/MEDLINE and Embase databases, selecting full-text English articles that have examined the sensibility and specificity of PET/CT for nodal staging or restaging after neoadjuvant therapy in patients with bladder cancer. The extracted data were analyzed and synthesized using a narrative synthesis approach. The results are presented in a tabular format, with a summary of the main findings of each study. Results: Twenty-three studies met the inclusion criteria: fourteen studies evaluated 18F-FDG PET/CT for nodal staging, six studies examined its accuracy for restaging after neoadjuvant therapy, and three studies evaluated both applications. To date, the use of F-18 FDG PET/TC for detection of LN metastasis in bladder cancer is controversial and uncertain: some studies showed low accuracy rates, but over the years other studies have reported evidence of high sensitivity and specificity. Conclusions: 18F-FDG PET/CT provides important incremental staging and restaging information that can potentially influence clinical management in MIBC patients. Standardization and development of a scoring system are necessary for its wider adoption. Well-designed randomized controlled trials in larger populations are necessary to provide consistent recommendations and consolidate the role of 18F-FDG PET/CT in the management of bladder cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. Impact of smoking on urologic cancers: a snapshot of current evidence.
- Author
-
Kumar, Raj, Matulewicz, Richard, Mari, Andrea, Moschini, Marco, Ghodoussipour, Saum, Pradere, Benjamin, Rink, Michael, Autorino, Riccardo, Desai, Mihir M., Gill, Inderbir, and Cacciamani, Giovanni E.
- Subjects
SMOKING cessation ,SMOKING ,PROSTATE cancer ,BLADDER cancer ,TOBACCO smoke ,DISEASE relapse ,LYMPHATIC metastasis - Abstract
Purpose: The purpose of this paper is to present evidence regarding the associations between smoking and the following urologic cancers: prostate, bladder, renal, and upper tract urothelial cancer (UTUC). Methods: This is a narrative review. PubMed was queried for evidence-based analyses and trials regarding the associations between smoking and prostate, bladder, renal, and UTUC tumors from inception to September 1, 2022. Emphasis was placed on articles referenced in national guidelines and protocols. Results: Prostate—multiple studies associate smoking with higher Gleason score, higher tumor stage, and extracapsular invasion. Though smoking has not yet been linked to tumorigenesis, there is evidence that it plays a role in biochemical recurrence and cancer-specific mortality. Bladder—smoking is strongly associated with bladder cancer, likely due to DNA damage from the release of carcinogenic compounds. Additionally, smoking has been linked to increased cancer-specific mortality and higher risk of tumor recurrence. Renal—smoking tobacco has been associated with tumorigenesis, higher tumor grade and stage, poorer mortality rates, and a greater risk of tumor recurrence. UTUC—tumorigenesis has been associated with smoking tobacco. Additionally, more advanced disease, higher stage, lymph node metastases, poorer survival outcomes, and tumor recurrence have been linked to smoking. Conclusion: Smoking has been shown to significantly affect most urologic cancers and has been associated with more aggressive disease, poorer outcomes, and tumor recurrence. The role of smoking cessation is still unclear, but appears to provide some protective effect. Urologists have an opportunity to engage in primary prevention by encouraging cessation practices. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators.
- Author
-
Del Giudice, Francesco, D'Andrea, David, Pradere, Benjamin, Berndl, Florian, Pallauf, Maximilian, Flammia, Rocco Simone, Philipp, Dominik, Moschini, Marco, Mari, Andrea, Albisinni, Simone, Krajewski, Wojciech, Laukhtina, Ekaterina, Gallioli, Andrea, Mertens, Laura S., Marcq, Gautier, Cimadamore, Alessia, Afferi, Luca, Gontero, Paolo, Shariat, Shahrokh F., and Chung, Benjamin I.
- Subjects
TRANSURETHRAL resection of bladder ,BLADDER cancer ,TUMOR surgery ,TRANSURETHRAL prostatectomy ,EXPERTISE ,UROLOGY ,CANCER invasiveness - Abstract
Objectives To address the association of perioperative surgical checklist across variable surgical expertise with transurethral resection of bladder tumour (TURBT) accuracy and oncological outcomes in non-muscle-invasive bladder cancer. Patients and Methods We relied on our prospective collaborative database of patients treated with TURBT between 2012 and 2017. Surgical experience was stratified into three groups: resident vs young vs expert consultants. The association of surgical experience with detrusor muscle (DM) presence and adherence to the standardised peri-procedural nine-items TURBT checklist was evaluated with logistic regression models. A Cox regression model was used to investigate the association of surgical experience with recurrence-free survival (RFS). Results A total of 503 patients were available for analysis. TURBT was performed by expert consultants in 265 (52.7%) patients, by young consultants in 149 (29.6%) and by residents in 89 (17.7%). Residents were more likely to have DM in the TURBT specimen than expert consultants (odds ratio [OR] 1.75, 95% confidence interval [CI] 1.03-2.99, P = 0.04). Conversely, no differences in DM presence were seen between young vs expert consultants (OR 1.09, 95% CI 0.71-1.70, P = 0.69). The median checklist completion rate was higher for both residents and young consultants when compared to experts' counterparts (56% and 56% vs 44%, P = 0.009). When focusing on patients receiving a second-look TURBT, the persistent disease was associated with resident status (OR 4.24, 95% CI 1.14-17.70, P = 0.037) at initial TURBT. Surgical experience was not associated with 5-years RFS. Conclusion Surgeon's experience in the case of adequate perioperative surgical checklist implementation was inversely associated with the presence of DM in the specimen but directly linked to higher probability of persistent disease at re-TURBT, although no 5-year RFS differences were noted. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer: a meta-analysis.
- Author
-
Yanagisawa, Takafumi, Quhal, Fahad, Tatsushi Kawada, Mostafaei, Hadi, Motlagh, Reza Sari, Laukhtina, Ekaterina, Rajwa, Pawel, von Deimling, Markus, Bianchi, Alberto, Pallauf, Maximilian, Majdoub, Muhammad, Pradere, Benjamin, Abufaraj, Mohammad, Moschini, Marco, Karakiewicz, Pierre I., Kosuke Iwatani, Jun Miki, Takahiro Kimura, and Shariat, Shahrokh F.
- Subjects
CANCER invasiveness ,BLADDER cancer ,CANCER patients ,TUMOR surgery ,CONFIDENCE intervals - Abstract
Objective To assess the association between cystoscopic findings and oncological outcomes in patients with non-muscle-invasive bladder cancer (NMIBC) given that the oncological impact of quantity and quality assessment of tumours with cystoscopy has not been well verified. Methods Multiple databases were queried in May 2022 for studies investigating the association of oncological outcomes, such as recurrence-free (RFS), progression-free (PFS), and cancer-specific survival (CSS), with cystoscopic findings, including multiplicity, size, and gross appearance of tumours in patients with NMIBC. Results Overall, 73 studies comprising 28 139 patients were eligible for the meta-analysis. Tumour multiplicity was associated with worse RFS (pooled hazard ratio [HR] 1.61, 95% confidence interval [CI] 1.48-1.74) and PFS (pooled HR 1.44, 95% CI 1.18-1.76) in NMIBC patients (including both Ta and T1). Tumour size (=3 cm) was associated with worse RFS (pooled HR 1.97, 95% CI 1.69-2.30) and PFS (pooled HR 1.81, 95% CI 1.52-2.15) in NMIBC patients. In patients with T1 bladder cancer (BCa), tumour multiplicity and size (=3 cm) were also associated with worse RFS, PFS and CSS. By contrast, among patients treated with bacillus Calmette-Guérin (BCG), tumour multiplicity was not associated with worse RFS, and tumour size (=3 cm) was not associated with worse PFS. Sessile tumours were associated with worse RFS (pooled HR 2.14, 95% CI 1.52-3.01) and PFS (pooled HR 2.17, 95% CI 1.42-3.32) compared to pedunculated tumours. Compared to papillary tumours, solid tumours were associated with worse RFS (pooled HR 1.84, 95% CI 1.25-2.72) and PFS (pooled HR 3.06, 95% CI 2.31-4.07) in NMIBC patients, and CSS in T1 BCa patients (pooled HR 2.32, 95% CI 1.63-3.30). Conclusions Cystoscopic findings, including tumour multiplicity, size, and gross appearance, strongly predict oncological outcomes in NMIBC patients. Cystoscopic visual features can help in the decision-making process regarding the timeliness and extent of tumour resection as well as future management such as intravesical therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate.
- Author
-
Laukhtina, Ekaterina, Moschini, Marco, Krajewski, Wojciech, Teoh, Jeremy Yuen‐Chun, Ploussard, Guillaume, Soria, Francesco, Roghmann, Florian, Muenker, Mara Anna, Roumiguie, Mathieu, Alvarez‐Maestro, Mario, Misrai, Vincent, Antonelli, Alessandro, Tafuri, Alessandro, Simone, Giuseppe, Mastroianni, Riccardo, Zhao, Hongda, Rahota, Razvan‐George, D'Andrea, David, Mori, Keiichiro, and Albisinni, Simone
- Subjects
- *
TRANSURETHRAL prostatectomy , *TRANSURETHRAL resection of bladder , *PATIENT safety , *DISEASE risk factors , *BENIGN prostatic hyperplasia , *PROPENSITY score matching - Abstract
Objectives: To determine the oncological impact and adverse events of performing simultaneous transurethral resection of bladder tumour (TURB) and transurethral resection of the prostate (TURP), as evidence on the outcomes of simultaneous TURB for bladder cancer and TURP for obstructive benign prostatic hyperplasia is limited and contradictory. Patients and Methods: Patients from 12 European hospitals treated with either TURB alone or simultaneous TURB and TURP (TURB+TURP) were retrospectively analysed. A propensity score matching (PSM) 1:1 was performed with patients from the TURB+TURP group matched to TURB‐alone patients. Associations between surgery approach with recurrence‐free (RFS) and progression‐free (PFS) survivals were assessed in Cox regression models before and after PSM. We performed a subgroup analysis in patients with risk factors for recurrence (multifocality and/or tumour size >3 cm). Results: A total of 762 men were included, among whom, 76% (581) underwent a TURB alone and 24% (181) a TURB+TURP. There was no difference in terms of tumour characteristics between the groups. We observed comparable length of stay as well as complication rates including major complications (Clavien–Dindo Grade ≥III) for the TURB‐alone vs TURB+TURP groups, while the latest led to longer operative time (P < 0.001). During a median follow‐up of 44 months, there were more recurrences in the TURB‐alone (47%) compared to the TURB+TURP group (28%; P < 0.001). Interestingly, there were more recurrences at the bladder neck/prostatic fossa in the TURB‐alone group (55% vs 3%, P < 0.001). TURB+TURP procedures were associated with improved RFS (hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.29–0.53; P < 0.001), but not PFS (HR 1.63, 95% CI 0.90–2.98; P = 0.11). Within the PSM cohort of 254 patients, the simultaneous TURB+TURP was still associated with improved RFS (HR 0.33, 95% CI 0.22–0.49; P < 0.001). This was also true in the subgroup of 380 patients with recurrence risk factors (HR 0.41, 95% CI 0.28–0.62; P < 0.001). Conclusion: In our contemporary cohort, simultaneous TURB and TURP seems to be an oncologically safe option that may, even, improve RFS by potentially preventing disease recurrence at the bladder neck and in the prostatic fossa. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
36. Re: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
- Author
-
Moschini, Marco, Necchi, Andrea, and Montorsi, Francesco
- Subjects
- *
CANCER invasiveness , *NIVOLUMAB , *BLADDER cancer , *CISPLATIN , *GEMCITABINE - Published
- 2024
- Full Text
- View/download PDF
37. Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis.
- Author
-
Del Giudice, Francesco, Asero, Vincenzo, Bologna, Eugenio, Scornajenghi, Carlo Maria, Carino, Dalila, Dolci, Virginia, Viscuso, Pietro, Salciccia, Stefano, Sciarra, Alessandro, D'Andrea, David, Pradere, Benjamin, Moschini, Marco, Mari, Andrea, Albisinni, Simone, Krajewski, Wojciech, Szydełko, Tomasz, Małkiewicz, Bartosz, Nowak, Łukasz, Laukhtina, Ekaterina, and Gallioli, Andrea
- Subjects
ONLINE information services ,MEDICAL databases ,META-analysis ,MEDICAL information storage & retrieval systems ,CONFIDENCE intervals ,SYSTEMATIC reviews ,CANCER relapse ,REGRESSION analysis ,NON-muscle invasive bladder cancer ,BCG vaccines ,QUALITY assurance ,DESCRIPTIVE statistics ,MEDLINE - Abstract
Simple Summary: Bacillus of Calmette-Guérin (BCG) is the gold standard as per adjuvant intravesical treatment for intermediate and high-risk non-muscle invasive bladder cancer (NMIBC). Nevertheless, drug-related toxicity, compliance, and a shortage of BCG availability make the completion of the planned treatment schedule challenging in many patients, thus possibly impacting survival outcomes. No one specific BCG strain out of the several available ones worldwide has so far demonstrated its superiority profile in prolonging time to recurrence and progression. In our systematic review and network meta-analysis, we compared to most widely adopted BCG strains and demonstrated that BCG strain Tice, RIVM, and Tokyo 172 could display potential enhanced benefits, thus possibly supporting the use of such strains for future BCG trials in NMIBCs. Background: In an era of Bacillus of Calmette-Guérin (BCG) shortages, the comparative efficacy from different adjuvant intravesical BCG strains in non-muscle invasive bladder cancer (NMIBC) has not been clearly elucidated. We aim to compare, through a systematic review and meta-analysis, the cumulative BC recurrence rates and the best efficacy profile of worldwide available BCG strains over the last forty years. Methods: PubMed, Scopus, Web of Science, Embase, and Cochrane databases were searched from 1982 up to 2022. A meta-analysis of pooled BC recurrence rates was stratified for studies with ≤3-y vs. >3-y recurrence-free survival (RFS) endpoints and the strain of BCG. Sensitivity analysis, sub-group analysis, and meta-regression were implemented to investigate the contribution of moderators to heterogeneity. A random-effect network meta-analysis was performed to compare BCG strains on a multi-treatment level. Results: In total, n = 62 series with n = 15,412 patients in n = 100 study arms and n = 10 different BCG strains were reviewed. BCG Tokyo 172 exhibited the lowest pooled BC recurrence rate among studies with ≤3-y RFS (0.22 (95%CI 0.16–0.28). No clinically relevant difference was noted among strains at >3-y RFS outcomes. Sub-group and meta-regression analyses highlighted the influence of NMIBC risk-group classification and previous intravesical treated categories. Out of the n = 11 studies with n = 7 BCG strains included in the network, BCG RIVM, Tice, and Tokyo 172 presented with the best-predicted probability for efficacy, yet no single strain was significantly superior to another in preventing BC recurrence risk. Conclusion: We did not identify a BCG stain providing a clinically significant lower BC recurrence rate. While these findings might discourage investment in future head-to-head randomized comparison, we were, however, able to highlight some potential enhanced benefits from the genetically different BCG RIVM, Tice, and Tokyo 172. This evidence would support the use of such strains for future BCG trials in NMIBCs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
38. A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy
- Author
-
Di Trapani, Ettore, Sanchez-Salas, Rafael, Gandaglia, Giorgio, Rocchini, Lorenzo, Moschini, Marco, Lizee, Daphne, Carneiro, Arie, Sivaraman, Arjun, Barret, Eric, Rozet, François, Galiano, Marc, Bennamoun, Mostefa, Colombo, Renzo, Suardi, Nazareno, Briganti, Alberto, Montorsi, Francesco, and Cathelineau, Xavier
- Published
- 2016
- Full Text
- View/download PDF
39. Differences in Cancer-Specific Mortality after Trimodal Therapy for T2N0M0 Bladder Cancer according to Histological Subtype.
- Author
-
Barletta, Francesco, Tappero, Stefano, Panunzio, Andrea, Incesu, Reha-Baris, Cano Garcia, Cristina, Piccinelli, Mattia Luca, Tian, Zhe, Gandaglia, Giorgio, Moschini, Marco, Terrone, Carlo, Antonelli, Alessandro, Tilki, Derya, Chun, Felix K. H., de Cobelli, Ottavio, Saad, Fred, Shariat, Shahrokh F., Montorsi, Francesco, Briganti, Alberto, and Karakiewicz, Pierre I.
- Subjects
BLADDER tumors ,CONFIDENCE intervals ,MORTALITY ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator ,DATA analysis software - Abstract
Simple Summary: Trimodal therapy represents an accepted treatment option for non-metastatic muscle-invasive bladder cancer, which is an alternative to radical cystectomy. Evidence regarding trimodal therapy efficacy has predominantly, or even exclusively, been applied to urothelial carcinoma of the urinary bladder patients. To address this void, we tested for differences in cancer-specific mortality in trimodal therapy-treated bladder cancer patients, according to histological subtype, namely urothelial carcinoma vs. neuroendocrine carcinoma vs. squamous cell carcinoma vs. adenocarcinoma. We aimed at assessing the impact of non-urothelial variant histology (VH), relative to urothelial carcinoma of the urinary bladder (UCUB), on cancer-specific mortality (CSM) in T2N0M0 bladder cancer patients treated with trimodal therapy (TMT). TMT patients treated for T2N0M0 bladder cancer were identified within the Surveillance, Epidemiology, and End Results database (2000−2018). Patients who underwent TMT received trans-urethral resection of the bladder tumor, chemotherapy, and radiotherapy. CSM-FS rates were tested using Kaplan–Meier plots and multivariable Cox-regression (MCR) models according to histological subtype: UCUB vs. neuroendocrine carcinoma vs. squamous cell carcinoma vs. adenocarcinoma. A total of 3846 T2N0MO bladder cancer patients treated with TMT were identified. Of these, 3627 (94.3%) harbored UCUB, while 105 (2.7%), 85 (2.2%), and 29 (0.8%) harbored neuroendocrine carcinoma, squamous cell carcinoma, and adenocarcinoma, respectively. In Kaplan–Meier analyses, 3-yr CSM-FS rates were 57% for UCUB, 51% for neuroendocrine carcinoma, 35% for squamous cell carcinoma, and 60% for adenocarcinoma (p-value < 0.0001). In MCR models, only squamous cell carcinoma exhibited higher CSM than UCUB (HR 1.98, 95%CI 1.5–2.61, p-value < 0.001). Despite the small number of observations, squamous cell carcinoma distinguished itself from UCUB based on worse survival in T2N0M0 patients after TMT. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
40. Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer.
- Author
-
Katayama, Satoshi, Schuettfort, Victor M., Pradere, Benjamin, Mori, Keiichiro, Mostafaei, Hadi, Quhal, Fahad, Sari Motlagh, Reza, Laukhtina, Ekaterina, Grossmann, Nico C., Aydh, Abdulmajeed, Rajwa, Pawel, König, Frederik, Karakiewicz, Pierre I., Haydter, Martin, Moschini, Marco, Abufaraj, Mohammad, Lotan, Yair, Lee, Richard K., Trinh, Quoc-Dien, and Compérat, Eva
- Subjects
HEPATOCYTE growth factor ,BLADDER cancer ,CANCER invasiveness ,PROGNOSIS ,CELL motility ,LOGISTIC regression analysis - Abstract
Purpose: The HGF/MET pathway is involved in cell motility, angiogenesis, proliferation, and cancer invasion. We assessed the clinical utility of plasma HGF level as a prognostic biomarker in patients with MIBC. Methods: We retrospectively analyzed 565 patients with MIBC who underwent radical cystectomy. Logistic regression and Cox regression models were used, and predictive accuracies were estimated using the area under the curve and concordance index. To estimate the clinical utility of HGF, DCA and MCID were applied. Results: Plasma HGF level was significantly higher in patients with advanced pathologic stage and LN metastasis (p = 0.01 and p < 0.001, respectively). Higher HGF levels were associated with an increased risk of harboring LN metastasis and non-organ-confined disease (OR1.21, 95%CI 1.12–1.32, p < 0.001, and OR1.35, 95%CI 1.23–1.48, p < 0.001, respectively) on multivariable analyses; the addition of HGF improved the predictive accuracies of a standard preoperative model (+ 7%, p < 0.001 and + 8%, p < 0.001, respectively). According to the DCA and MCID, half of the patients had a net benefit by including HGF, but the absolute magnitude remained limited. In pre- and postoperative predictive models, a higher HGF level was significant prognosticator of worse RFS, OS, and CSS; in the preoperative model, the addition of HGF improved accuracies by 6% and 5% for RFS and CSS, respectively. Conclusion: Preoperative HGF identified MIBC patients who harbored features of clinically and biologically aggressive disease. Plasma HGF could serve, as part of a panel, as a biomarker to aid in preoperative treatment planning regarding intensity of treatment in patients with clinical MIBC. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
41. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis
- Author
-
Laukhtina, Ekaterina, Shim, Sung Ryul, Mori, Keiichiro, D'Andrea, David, Soria, Francesco, Rajwa, Pawel, Mostafaei, Hadi, Compérat, Eva, Cimadamore, Alessia, Moschini, Marco, Teoh, Jeremy Yuen-Chun, Enikeev, Dmitry, Xylinas, Evanguelos, Lotan, Yair, Palou, Juan, Gontero, Paolo, Babjuk, Marko, Witjes, Johannes Alfred M., Kamat, Ashish Madhav, Roupret, Morgan, Shariat, Shahrokh F, Pradere, Benjamin, and Universitat Autònoma de Barcelona
- Subjects
medicine.medical_specialty ,Urology ,Urinary system ,Network Meta-Analysis ,Context (language use) ,Accuracy ,Bladder cancer ,Urinary biomarkers ,Urine cytology ,Biomarkers ,Tumor ,Cystoscopy ,Humans ,Neoplasm Recurrence ,Local ,Urinary Bladder Neoplasms ,Internal medicine ,Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15] ,medicine ,Clinical endpoint ,Biomarkers, Tumor ,Radiology, Nuclear Medicine and imaging ,medicine.diagnostic_test ,business.industry ,medicine.disease ,Cystoscopies ,Neoplasm Recurrence, Local ,Oncology ,Meta-analysis ,Biomarker (medicine) ,Surgery ,business - Abstract
Contains fulltext : 244217.pdf (Publisher’s version ) (Open Access) CONTEXT: During the past decade, several urinary biomarker tests (UBTs) for bladder cancer have been developed and made commercially available. However, none of these is recommended by international guidelines so far. OBJECTIVE: To assess the diagnostic estimates of novel commercially available UBTs for diagnosis and surveillance of non-muscle-invasive bladder cancer (NMIBC) using diagnostic test accuracy (DTA) and network meta-analysis (NMA). EVIDENCE ACQUISITION: PubMed, Web of Science, and Scopus were searched up to April 2021 to identify studies addressing the diagnostic values of UBTs: Xpert bladder cancer, Adxbladder, Bladder EpiCheck, Uromonitor and Cxbladder Monitor, and Triage and Detect. The primary endpoint was to assess the pooled diagnostic values for disease recurrence in NMIBC patients using a DTA meta-analysis and to compare them with cytology using an NMA. The secondary endpoints were the diagnostic values for high-grade (HG) recurrence as well as for the initial detection of bladder cancer. EVIDENCE SYNTHESIS: Twenty-one studies, comprising 7330 patients, were included in the quantitative synthesis. In most of the studies, there was an unclear risk of bias. For NMIBC surveillance, novel UBTs demonstrated promising pooled diagnostic values with sensitivities up to 93%, specificities up to 84%, positive predictive values up to 67%, and negative predictive value up to 99%. Pooled estimates for the diagnosis of HG recurrence were similar to those for the diagnosis of any-grade recurrence. The analysis of the number of cystoscopies potentially avoided during the follow-up of 1000 patients showed that UBTs might be efficient in reducing the number of avoidable interventions with up to 740 cystoscopies. The NMA revealed that diagnostic values (except specificity) of the novel UBTs were significantly higher than those of cytology for the detection of NMIBC recurrence. There were too little data on UBTs in the primary diagnosis setting to allow a statistical analysis. CONCLUSIONS: Our analyses support high diagnostic accuracy of the studied novel UBTs, supporting their utility in the NMIBC surveillance setting. All of these might potentially help prevent unnecessary cystoscopies safely. There are not enough data to reliably assess their use in the primary diagnostic setting. These results have to be confirmed in a larger cohort as well as in head-to-head comparative studies. Nevertheless, our study might help policymakers and stakeholders evaluate the clinical and social impact of the implementation of these tests into daily practice. PATIENT SUMMARY: Novel urinary biomarker tests outperform cytology with the potential of improving routine clinical practice by preventing unnecessary cystoscopic examinations during the surveillance of non-muscle-invasive bladder cancer.
- Published
- 2021
42. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
- Author
-
Padua, Tiago Costa de, Moschini, Marco, Martini, Alberto, Pederzoli, Filippo, Nocera, Luigi, Marandino, Laura, Raggi, Daniele, Briganti, Alberto, Montorsi, Francesco, and Necchi, Andrea
- Subjects
- *
ANTIBODY-drug conjugates , *TRANSITIONAL cell carcinoma , *CLINICAL trials , *METASTASIS , *ADVERSE health care events , *BLADDER cancer - Abstract
Introduction: Metastatic urothelial cancer (mUC) is an aggressive disease with limited overall survival and treatment options. Antibody-drug conjugates (ADCs) were designed with the intent to deliver potent cytotoxic drugs selectively to antigen-expressing tumor cells by linking cytotoxins to monoclonal antibodies (mAbs) and have emerged as new treatment options in mUC, mainly in chemotherapy (CT) and immune-checkpoint inhibitors (ICI)-exposed patients. We aimed to perform a scoping review to assess activity, efficacy, treatment-related adverse events (TRAEs), and impact on quality of life of ADCs in mUC.Methods: A review of the literature was performed in January 2022 using Pubmed and Embase databases according to the recommendations of the Joanna Briggs Institute. The search method involved querying for the terms "bladder carcinoma" or "urothelial carcinoma" with any of the following: "enfortumab vedotin" (EV), "sacituzumab govitecan" (SG), antibody-drug conjugate. Only prospective clinical trials were included.Results: Ultimately, eleven clinical trials with 1417 patients were selected for inclusion, and five drugs were identified: enfortumab vedotin (EV), sacituzumab govitecan (SG), disitamab vedotin (RC48-ADC), ASG-15ME (anti-SLITRK6), and trastuzumab deruxtecan. The different ADCs have been tested mainly in phase 1 or phase 2 trials, as monotherapy or in combination with ICI. Response rate ranged from 27% with SG in previously treated patients to 73.3% with EV plus pembrolizumab in cisplatin-ineligible patients as first-line treatment. The phase 3 trial, EV-301, confirmed EV superiority over investigator-chosen CT after failure to platinum-based CT and ICI, improving overall survival (12.88 vs. 8.97 months; HR 0.70; 95% CI, 0.56-0.89; P=0.001). TRAEs of any grade occurred in more than 90% of patients in phase 2 or 3 trials, with high rates of grade 3 ≥ events ranging from 51.4 to 73.5% in different trials. TRAEs of particular interest related to EV were rash, neuropathy, and hyperglycemia. SG was associated with diarrhea and hematologic toxicity. Data from phase 2 and 3 trials of EV suggest no impact on quality of life but an improvement in pain symptoms compared to the control arm.Conclusions: ACDs represent a new therapeutic option for the treatment of mUC. Level-1 evidence has already been achieved by EV in the post-CT and post-ICI settings. A high incidence of potential adverse events was observed in phase 2 and 3 trials, including rash, neutropenia, hematologic toxicity, and neuropathy. Clinicians should be aware of possible adverse events and their optimal management. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
43. MP71-14 LONG TERM OUTCOMES OF LOW AND INTERMEDIATE RISK BLADDER CANCER PATIENTS TREATED WITH TRANSURETHRAL RESECTION ELIGIBLE FOR ACTIVE SURVEILLANCE.
- Author
-
Scilipoti, Pietro, Giulio, Avesani, Longoni, Mattia, Mario, De Angelis, Re, Chiara, Quarta, Leonardo, Bertini, Alessandro, Burgio, Giusy, Pellegrino, Francesco, Rosiello, Giuseppe, Necchi, Andrea, Raggi, Daniele, Lucianò, Roberta, Capitanio, Umberto, Gandaglia, Giorgio, Colombo, Renzo, Salonia, Andrea, Montorsi, Francesco, Briganti, Alberto, and Moschini, Marco
- Subjects
WATCHFUL waiting ,BLADDER cancer ,CANCER patients ,DISEASE risk factors ,NON-muscle invasive bladder cancer - Published
- 2024
- Full Text
- View/download PDF
44. MP71-07 THE IMPACT OF CENTRALIZED UROPATHOLOGY REVIEW IN THE MANAGEMENT OF BLADDER CANCER PATIENTS AT THE TIME OF TRANSURETHRAL RESECTION OF THE BLADDER.
- Author
-
Robesti, Daniele, Moschini, Marco, Tenace, Nazario Pio, Burgio, Giusy, Re, Chiara, Leni, R.Iccardo, De Angelis, Mario, Scilipoti, Pietro, Pellegrino, Francesco, Cannoletta, Donato, Gandaglia, Giorgio, Fossati, Nicola, Gallina, Andrea, Doglioni, Claudio, Colecchia, Maurizio, Salonia, Andrea, Montorsi, Francesco, Briganti, Alberto, and Lucianò, Roberta
- Subjects
TRANSURETHRAL resection of bladder ,BLADDER cancer ,CANCER patients ,NON-muscle invasive bladder cancer - Published
- 2024
- Full Text
- View/download PDF
45. MP53-04 NEOADJUVANT VERSUS ADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER: A DECISION ANALYSIS.
- Author
-
Afferi, Luca, Jahn, Beate, Fankhauser, Christian D., Cathomas, Richard, Bellmunt, Joaquim, Moschini, Marco, Mattei, Agostino, Chang, Steven L., and Siebert, Uwe
- Subjects
CANCER invasiveness ,DECISION making ,BLADDER cancer - Published
- 2024
- Full Text
- View/download PDF
46. PD34-12 THE OPTIMAL NUMBER OF INDUCTION CHEMOTHERAPY CYCLES IN CLINICALLY LYMPH NODE-POSITIVE BLADDER CANCER.
- Author
-
von Deimling, Markus, Mertens, Laura S., Furrer, Marc, Li, Roger, Tendijck, Guus A. H., Taylor, Jacob, Crocetto, Felice, Maas, Moritz, Mari, Andrea, Pichler, Renate, Moschini, Marco, Tully, Karl H., D'Andrea, David, Laukhtina, Ekaterina, Del Giudice, Francesco, Marcq, Gautier, Velev, Maud, Gallioli, Andrea, Albisinni, Simone, and Mori, Keiichiro
- Subjects
INDUCTION chemotherapy ,BLADDER cancer - Published
- 2024
- Full Text
- View/download PDF
47. PD34-10 FIRST RESULTS OF NURE-COMBO: a PHASE 2 STUDY OF NEOADJUVANT NIVOLUMAB (NIVO) AND NAB-PACLITAXEL (ABX) FOLLOWED BY POSTSURGICAL ADJUVANT NIVO IN PATIENTS (PTS) WITH MUSCLE-INVASIVE BLADDER CANCER (MIBC).
- Author
-
Necchi, Andrea, Mercinelli, Chiara, Basile, Giuseppe, Raggi, Daniele, Cigliola, Antonio, Tateo, Valentina, Patanè, Damiano, Crupi, Emanuele, Colecchia, Maurizio, Moschini, Marco, Avesani, Giulio, Brembilla, Giorgio, De Cobelli, Francesco, Briganti, Alberto, Ross, Jeffrey, and Montorsi, Francesco
- Subjects
CANCER invasiveness ,BLADDER cancer ,NIVOLUMAB ,PATHOLOGIC complete response ,CIRCULATING tumor DNA ,NEOADJUVANT chemotherapy - Published
- 2024
- Full Text
- View/download PDF
48. MP38-20 RISK OF UPPER URINARY TRACT DISSEMINATION IN cT3 BLADDER CANCER PATIENTS TREATED WITH DOUBLE-J STENT VERSUS NEPHROSTOMY TUBE PRIOR TO RADICAL CYSTECTOMY.
- Author
-
de Angelis, Mario, Soria, Francesco, Pradere, Benjamin, Afferi, Luca, Montorsi, Francesco, Briganti, Alberto, Shariat, Shahrokh F., Wiklund, Peter, D'Andrea, David, Albissini, Simone, Mari, Andrea, Del Giudice, Francesco, Krajewski, Wojciech, Laukhtina, Ekaterina, Yuen-Chun Teoh, Jeremy, Mori, Keiichiro, Mertens, Laura S., Gallioli, Andrea, Pichler, Renate, and Moschini, Marco
- Subjects
URINARY organs ,BLADDER cancer ,CANCER patients ,URINARY diversion ,NEPHROSTOMY ,CYSTECTOMY ,ILEAL conduit surgery - Published
- 2024
- Full Text
- View/download PDF
49. PD30-06 PHOTODYNAMIC DIAGNOSIS (PDD) DIRECTED BIOPSIES VS WHITE LIGHT BLADDER MAPPING IN PATIENTS WITH POSITIVE CYTOLOGY AND NEGATIVE PREOPERATIVE WORKUP: AN INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY.
- Author
-
Colucci, Fulvia, Soria, Francesco, Livoti, Simone, Rosazza, Matteo, Dutto, Daniele, Marcq, Gautier, Jarry, Edouard, Mertens, Laura, Moschini, Marco, Deangelis, Mario, Longoni, Mattia, Hurle, Rodolfo, Mancon, Stefano, Pichler, Renate, Lackner, Felizian, Montorsi, Francesco, and Gontero, Paolo
- Subjects
BLADDER ,CYTOLOGY ,DIAGNOSIS ,BLADDER cancer ,RETROSPECTIVE studies - Published
- 2024
- Full Text
- View/download PDF
50. PD02-06 COMPREHENSIVE GENOMIC PROFILING (CGP) OF CLINICAL T2-4N0M0 MUSCLE-INVASIVE BLADDER CANCER (MIBC) TREATED WITH NEOADJUVANT PEMBROLIZUMAB OR CISPLATIN-BASED CHEMOTHERAPY BEFORE RADICAL CYSTECTOMY (RC).
- Author
-
Necchi, Andrea, Mercinelli, Chiara, Raggi, Daniele, Tateo, Valentina, Cigliola, Antonio, Patanè, Damiano, Crupi, Emanuele, Colecchia, Maurizio, Moschini, Marco, Avesani, Giulio, Briganti, Alberto, Montorsi, Francesco, Pavlick, Dean, and Ross, Jeffrey
- Subjects
BLADDER cancer ,CANCER invasiveness ,ILEAL conduit surgery ,PEMBROLIZUMAB ,CYSTECTOMY ,CANCER chemotherapy ,TUMOR markers - Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.